Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7492MR)

This product GTTS-WQ7492MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7492MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2840MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ1652MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ10039MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ10670MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ1691MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ6177MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-751871
GTTS-WQ14665MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ12205MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW